Business

MSD Innovation Factory is looking for digital solutions for anaesthesiologists

MSD is looking for innovators to solve 7 health-related challenges. One of them seeks to support anaesthesiologists with their continuous education (e.g. at the operation room) or their team building with surgeons. As a leading pharmaceutical company, MSD is aware of the need to incorporate innovation to deliver the best possible value to healthcare professionals, patients and customers.

Kazakhstan - New regulations for medicinal products in the pipeline

The Ministry of Health in Kazakhstan is introducing changes to the existing legislation for distribution of pharmaceutical products and medical devices with the view to improve regulation of prices and 'create a patient-oriented drug provision model.' According to a new draft law, in October 2018 regulated prices will be introduced for all prescription pharmaceutical products with OTC drugs following suit in 2023.

Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams

Roche (SIX: RO, ROG; OTCQX:RHHBY), has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings. The solution fundamentally changes the way these meetings are organised and conducted.

Sanofi and Regeneron announce approval of Dupixent® (dupilumab) to treat adult patients with moderate-to-severe atopic dermatitis in the European Union

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for Dupixent® (dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy. Atopic dermatitis, a form of eczema, is a chronic inflammatory disease with symptoms often appearing as a rash on the skin.

Amgen to begin launching biosimilar adalimumab in Europe in 2018

Amgen (NASDAQ:AMGN) today announced that it has reached a global settlement with AbbVie to resolve all pending litigation regarding AMGEVITATM/AMJEVITATM, a biosimilar to AbbVie's Humira® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of AMGEVITA/AMJEVITA worldwide, on a country-by-country basis, and the companies have agreed to dismiss all pending litigation.

Up to $20,000 available to the digital health company that solves one of the challenges proposed by MSD

MSD is looking for innovators to solve 7 health-related challenges aiming to support physician education or patient disease management. The 3 digital solutions with the most outstanding value will receive up to $20,000 each to be launched in a local market. MSD will also work side by side with the winning solvers to facilitate the roll-out of their solution.

Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program

Daiichi Sankyo Company, Limited today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Global 2018, a collaborative drug discovery initiative for universities and research institutes in Europe and the East Coast of the United States.

Business

More Pharma News ...